Logo

Merck’s MK-2060 Receives the US FDA’s Fast Track Designation for the Treatment of End-Stage Renal Disease

Share this

Merck’s MK-2060 Receives the US FDA’s Fast Track Designation for the Treatment of End-Stage Renal Disease

Shots:

  • The US FDA has granted FTD to MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD
  • MK-2060 is currently being evaluated in the P-II study to evaluate the efficacy & safety of two different doses in patients with ESRD who received hemodialysis via an arteriovenous graft (AVG). Future studies using MK-2060 will benefit from the data from this trial to help with dose selection
  • MK-2060 is a novel inhibitor of Factor XI & is indicated for the prevention of thrombosis in patients with ESRD. The therapy is intended to function by preventing both the downstream activity of the activated protein and the activation of Factor XI

Ref: Businesswire | Image: Merck

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions